Provides Daré access to capital at Daré’s discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential ...
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 ...
Dare Bioscience Inc. Annual cash flow by MarketWatch. View DARE net cash flow, operating cash flow, operating expenses and cash dividends.
Short interest in Dare Bioscience Inc (NASDAQ:DARE) decreased during the last reporting period, falling from 716.07K to 691.07K. This put 4.64% of the company's publicly available shares short. Based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results